Skip to search formSkip to main contentSkip to account menu

BEZ235

Known as: PI3K/mTOR Inhibitor BEZ235 
An orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

dactolisib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance.
2015
2015
ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
2014
2014
Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Phospholipid metabolites are of importance in cancer studies, and have been suggested as candidate metabolic biomarkers for… 
2014
2014
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Introduction: The PI3K signaling pathway drives tumor cell proliferation and survival in gastrointestinal stromal tumor (GIST… 
2014
2014
Tuneable radical cyclisations: a tin-free approach towards tricyclic and spirocyclic heterocycles via a common precursor
A novel common precursor approach towards both tricyclic and spirocyclic heterocycles is described. Cyclisations are based on… 
Review
2013
Review
2013
Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Over the last few years, there have been important advances in the understanding of the molecular biology of neuroendocrine… 
Highly Cited
2012
Highly Cited
2012
Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Mutant KRAS is a feature of more than 25% of non–small cell lung cancers (NSCLC) and represents one of the most prevalent… 
2012
2012
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells
Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved… 
Highly Cited
2011
Highly Cited
2011
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Purpose: In thyroid cancer clinical trials, agents targeting VEGF receptors (VEGFR) and RET, among other kinases, have led to… 
2011
2011
Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
Purpose: In this study, we tested the antitumor activity of the dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor BEZ235… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)